1609962-87-9

Upstream product

• 1279865-14-3 2-amino-4-bromo-6-fluoro-benzonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1609962-99-3 N′-[2-cyano-5-[[dimethyl(oxo)-λ⁶-sulfanylidene]amino]-3-hydroxyphenyl]-N,N-dimethylformamidine 
• 1609963-01-0 N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine 
• 1609960-66-8 C₂₀H₂₁FN₄O₄S 
• 1609960-67-9 C₂₁H₂₁F₃N₄O₄S 
• 1609963-02-1 N'-[2-cyano-3-(difluoromethoxy)-5-[[dimethyl(oxo)-λ⁶-sulfanylidene]amino]phenyl]-N,N-dimethylformamidine 
• 1609962-93-7 N'-(5-bromo-2-cyano-3-methoxyphenyl)-N,N-dimethylformamidine 
• 1609963-00-9 N'-(5-bromo-2-cyano-3-fluorophenyl)-N,N-dimethylformamidine 

Relevant academic research and scientific papers

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I) wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1 a or MNK1 b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.

SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS

This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.